GILD•benzinga•
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Summary
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga